- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05299177
Feasibility of Automated Insulin Delivery With an Interoperable Algorithm Using an Alternative Insulin Pump (BELIEVE)
Visão geral do estudo
Descrição detalhada
Self-management of type 1 diabetes is challenging, efforts to optimise time spent in the target range can result in hypo- and hyperglycaemia. Structured education, glucose monitoring and advances in insulin delivery can increase time in range and reduce exposure to extremes of glucose and recent data confirm that automated insulin delivery can enable further increases in time spent in the target range of 3.9 to 10mmol/L (70 - 180mg/dL).
The inControl algorithm, developed by TypeZero technologies is embedded in the Tandem X2 insulin pump and operates with the Dexcom G6 continuous glucose sensor and transmitter in a CE-marked and commercially available system (known as Control-IQ). This system optimises time in range compared with sensor-augmented pump therapy, and the improvement was maintained when participants were further randomised to predictive low glucose suspend or automated insulin delivery. The United States Food and Drug Administration has defined interoperable standards for automated insulin delivery systems, including the iCGM designation for continuous glucose sensors, the interoperable automated glycaemic controller designation, and alternate controller enabled insulin pumps. However, while standards have been defined, to date, interoperability of automated insulin delivery components has not been demonstrated.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Nick Oliver
- Número de telefone: 07957163617
- E-mail: nick.oliver@imperial.ac.uk
Locais de estudo
-
-
-
London, Reino Unido, W2 1PG
- Recrutamento
- Imperial College London, Imperial College Healthcare NHS Trust
-
Contato:
- Nick Oliver
- E-mail: nick.oliver@imperial.ac.uk
-
Investigador principal:
- Monika Reddy, MRCP
-
Investigador principal:
- Nick Oliver, FRCP
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Aged 18 years of age or older
- Type 1 diabetes confirmed on the basis of clinical features
- Type 1 diabetes for greater than 1 year
- On an intensified insulin regimen with multiple dose injection or insulin pump for > 3 months
- HbA1c >7.5% (58mmol/mol) (or %TIR 3.9-10mmol/L <52% for participants already using a continuous glucose sensor)
Exclusion Criteria:
- Total daily insulin dose greater than 100 units
- Weight greater than 140kg
- Pregnant or planning pregnancy
- Have active malignancy or under investigation for malignancy
- Severe visual impairment
- Reduced manual dexterity
- Use of any automated insulin delivery system
- Unable to participate due to other factors, as assessed by the Chief Investigator
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Viabilidade do dispositivo
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Automated Insulin Delivery
The components of the automated insulin delivery system are the Dexcom G6 continuous glucose monitor (CGM), the InControl algorithm and an insulin pump (Ypsomed Ypsopump).
The Dexcom G6 continuous glucose monitoring device is an approved device and is licensed to be used to inform insulin dosing decisions without confirmation.
The algorithm (inControl 1.0) is approved when used embedded in the Tandem X2 insulin pump.
We are using the algorithm for its intended purpose but are implementing it in a smartphone app to be installed in a compatible smartphone (Android).
We are additionally assessing incremental benefit with the next software version of the algorithm.
This will be the first time this updated software has been assessed in people with type 1 diabetes.
The compatible insulin pump is a continuous subcutaneous insulin infusion device and is being used in line with its intended purpose, according to the manufacturer's instructions (YpsoMed Ypsopump).
|
Automated insulin delivery system comprising continuous glucose sensor (Dexcom G6), controller (InControl embedded in smartphone app) and insulin pump (YpsoMed Ypsopump)
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
% time spent in target glucose range measured by continuous glucose monitoring (3.9-10mmol/L, 70-180mg/dL)
Prazo: Extracted from the final 28 days of the intervention period
|
Consensus measure of time in range
|
Extracted from the final 28 days of the intervention period
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
% time spent in hypoglycaemia (<3.0mmol/L, 54mg/dL)
Prazo: Extracted from the final 28 days of the intervention period
|
Consensus measure of time in range
|
Extracted from the final 28 days of the intervention period
|
% time spent in hypoglycaemia (<3.9mmol/L, 70mg/dL)
Prazo: Extracted from the final 28 days of the intervention period
|
Consensus measure of time in range
|
Extracted from the final 28 days of the intervention period
|
% time in euglycaemia (3.9-7.8mmol/L, 70-140mg/dL)
Prazo: Extracted from the final 28 days of the intervention period
|
Consensus measure of time in range
|
Extracted from the final 28 days of the intervention period
|
% time spent in hyperglycaemia (>10mmol/L, 180mg/dL)
Prazo: Extracted from the final 28 days of the intervention period
|
Consensus measure of time in range
|
Extracted from the final 28 days of the intervention period
|
Number hypoglycaemic excursions (sensor glucose <3.0mmol/l for >= 20min)
Prazo: Over 12 week intervention period
|
Consensus measure of exposure to hypoglycaemia
|
Over 12 week intervention period
|
Nocturnal Severe hypoglycaemia (defined as requiring third party assistance)
Prazo: Over 12 week intervention period
|
Consensus measure of exposure to hypoglycaemia
|
Over 12 week intervention period
|
Severe hypoglycaemia (defined as requiring third party assistance)
Prazo: Over 12 week intervention period
|
Consensus measure of exposure to hypoglycaemia
|
Over 12 week intervention period
|
Glucose variability assessed by %Coefficient of Variation (%CV)
Prazo: Extracted from the final 28 days of the intervention period
|
Consensus measure of glucose variability
|
Extracted from the final 28 days of the intervention period
|
Glucose variability assessed by Mean Absolute Glucose (MAG)
Prazo: Extracted from the final 28 days of the intervention period
|
Consensus measure of glucose variability
|
Extracted from the final 28 days of the intervention period
|
Glucose variability assessed by Low Blood Glucose Index (LBGI)
Prazo: Extracted from the final 28 days of the intervention period
|
Consensus measure of glucose variability
|
Extracted from the final 28 days of the intervention period
|
HbA1c
Prazo: At end of 12 week intervention period
|
Laboratory HbA1c assessment
|
At end of 12 week intervention period
|
Time spent in automated insulin delivery mode
Prazo: Over 12 week intervention period
|
% of total time that automated insulin delivery is active
|
Over 12 week intervention period
|
Treatment satisfaction (DTSQ, AP acceptability)
Prazo: At end of 12 week intervention period
|
Validated patient reported outcome
|
At end of 12 week intervention period
|
Gold score
Prazo: At end of 12 week intervention period
|
Validated patient reported outcome of hypoglycaemia awareness (1-7, with greater value indicating loss of awareness)
|
At end of 12 week intervention period
|
Diabetes distress (DDS-17)
Prazo: At end of 12 week intervention period
|
Validated patient reported outcome, Diabetes Distress Score 17 item, higher scores mean greater distress
|
At end of 12 week intervention period
|
Diabetes distress (PAID)
Prazo: At end of 12 week intervention period
|
Validated patient reported outcome, Problem Areas In Diabetes 20 item
|
At end of 12 week intervention period
|
Change in total daily insulin dose (units)
Prazo: At end of 12 week intervention period
|
Total insulin delivered by system per day
|
At end of 12 week intervention period
|
Change in weight (kg)
Prazo: At end of 12 week intervention period
|
Weight in kg
|
At end of 12 week intervention period
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Direct Resource Utilisation Costs
Prazo: Over 12 week intervention period
|
Health economic modelling exploratory outcome
|
Over 12 week intervention period
|
Indirect Costs
Prazo: Over 12 week intervention period
|
Health economic modelling exploratory outcome
|
Over 12 week intervention period
|
Productivity lost
Prazo: Over 12 week intervention period
|
Health economic modelling exploratory outcome
|
Over 12 week intervention period
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 20HH5892
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Diabetes tipo 1
-
Oxford Brookes UniversityUniversity of OxfordConcluídoAtividade física | Saúde Mental Bem-estar 1 | Função Cognitiva 1, Social | Academic Attainment | Fitness TestingReino Unido
-
Merck Sharp & Dohme LLCRecrutamentoCâncer de Pulmão de Células Não Pequenas | Tumores Sólidos | Morte Celular Programada-1 (PD1, PD-1) | Ligante 1 de morte celular programada 1 (PDL1, PD-L1) | Ligante 2 de morte celular programada 1 (PDL2, PD-L2)Japão
-
National Cancer Institute, NaplesRecrutamentoCâncer de Ovário Recorrente Sensível à Platina BRCA Wild TypeItália
-
Rambam Health Care CampusIsrael Science FoundationConcluído
-
Alvotech Swiss AGConcluído
-
PfizerConcluído
-
SanionaConcluído
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionConcluído
-
Calliditas Therapeutics ABConcluído
-
Reproductive Medicine Associates of New JerseyConcluídoCada paciente é tanto caso quanto controle | 1 embrião será biopsiado e 1 embrião não seráEstados Unidos
Ensaios clínicos em InControl
-
University Health Network, TorontoDesconhecido
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); DexCom... e outros colaboradoresConcluídoDiabetes Mellitus, Tipo 1Estados Unidos, Holanda, França, Itália
-
University Hospital, MontpellierUniversity of Virginia; Jaeb Center for Health Research; MEDBIOMED, Montpellier...Rescindido
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Stanford... e outros colaboradoresConcluídoDiabetes mellitus tipo 1Estados Unidos